Trial intelligence / Profile preview

Sitagliptin as add-on to pioglitazone for type 2 diabetes

NCT00086502Phase 3Completed

Sponsor
Merck & Co.
Start
Jun 2004
Primary completion
Nov 2005
Modality
Small Molecules
01

Overview

A Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Jun 2004; status: completed.

02

Drugs

sitagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT00086502.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00086502.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call